AYTU
Aytu BioPharma, Inc.
AYTU lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
AYTU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Stable | |
| Strong |
AYTU's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are under pressure.
AYTU PE Valuation
AYTU has no meaningful PE right now: it lost money over the past year.
AYTU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect AYTU's losses to shrink, with revenue growing.
AYTU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.66 | +$0.96 |
| Q1 2026 | -$4.08 | -$3.05 |
| Q4 2025 | -$3.34 | -$1.58 |
| Q3 2025 | -$2.55 | -$1.01 |
| Q2 2025 | -$2.62 | +$0.25 |
| Q1 2025 | -$1.03 | +$1.76 |
| Q4 2024 | -$1.76 | +$2.44 |
| Q3 2024 | -$1.54 | +$4.77 |
AYTU is still losing money, but far less than before: $1.66 per share over the past year, against $85.40 at its worst in early 2022.
AYTU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.1M | +6.4% |
| Q1 2026 | $12.4M | -33% |
| Q4 2025 | $15.2M | -6.5% |
| Q3 2025 | $13.9M | -16% |
| Q2 2025 | $15.1M | -16% |
| Q1 2025 | $18.5M | +2.6% |
| Q4 2024 | $16.2M | -29% |
| Q3 2024 | $16.6M | -25% |
AYTU's revenue is recovering but still below its 2023 peak: $16M last quarter, up 6.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4.8% | +46 points |
| Q1 2026 | -33% | -46 points |
| Q4 2025 | -13% | -2.5 points |
| Q3 2025 | -11% | -5.2 points |
| Q2 2025 | -50% | -30 points |
| Q1 2025 | 13% | +27 points |
| Q4 2024 | -10% | -21 points |
| Q3 2024 | -5.6% | +1.2 points |
AYTU's operating margin was −4.8% last quarter, up 46 points from the same quarter a year ago.
AYTU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.4M | +58% |
| Q1 2026 | -$4.2M | +$2.3M |
| Q2 2025 | $2.8M | +$3.6M |
| Q1 2025 | -$6.5M | -$6.3M |
| Q2 2024 | -$788K | -108% |
| Q1 2024 | -$254K | +$2.7M |
| Q4 2023 | -$135K | +$2.3M |
| Q3 2023 | -$211K | +$8.9M |
AYTU's free cash flow has turned positive after five years mostly in the red: $3M over the past year.
AYTU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +1.8M shares |
| 1 year | +50% | +4.1M shares |
| 3 years | +296% | +9.2M shares |
| 5 years | +6884% | +12.1M shares |
AYTU has 12M diluted shares, up 50% from a year ago.
AYTU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -1.8x | Net Cash |
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -3.8x | Net Cash |
AYTU has more cash than debt.
AYTU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.9 | Neutral |
| Stochastic | 8.0 | Oversold |
AYTU's weekly RSI is 36 (neutral) and its Stochastic is 8 (oversold).
AYTU PE vs Healthcare Sector
AYTU has no meaningful PE right now: it lost money over the past year.
AYTU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.98 | 9.6% below |
| 20 week MA | $2.12 | 16% below |
| 50 week MA | $2.32 | 23% below |
| 100 week MA | $2.08 | 14% below |
| 200 week MA | $2.27 | 21% below |
AYTU is in a downtrend: it's below all five of its weekly moving averages, and 21% below its 200-week average.
AYTU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $196.0 | $122.4 | -38% |
| 2021 | $122.4 | $30.4 | -75% |
| 2022 | $30.4 | $3.80 | -88% |
| 2023 | $3.80 | $2.84 | -25% |
| 2024 | $2.84 | $1.52 | -46% |
| 2025 | $1.52 | $2.45 | +61% |
| 2026 YTD | $2.45 | $1.79 | -27% |
AYTU has finished lower in five of the last six years. It's down 27% so far in 2026.